Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS
This study has been completed.
Study NCT00038831 Information provided by M.D. Anderson Cancer Center
First Received: June 5, 2002 Last Updated: October 22, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Acute Myelogenous Leukemia
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Additional conditions recognized in this trial
Leukemia
Leukemia, B-Cell
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Preleukemia
Syndrome
More general conditions related to this trial
Bone Marrow Diseases
Disease
Hematologic Diseases
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Pathologic Processes
Precancerous Conditions
Interventions listed in this trial
Mylotarg
Fludarabine
Melphalan
Anti-thymocyte globulin
Stem cell transplant
Additional drug interventions recognized in this trial
Antibodies, Monoclonal
Antilymphocyte Serum
Fludarabine monophosphate
Gemtuzumab
Vidarabine
More general drug interventions related to this trial
Alkylating Agents
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antiviral Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
M.D. Anderson Cancer Center
Back to top of Main Content
